Overview

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.

Phase:

Phase 2

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborator:

National Cancer Institute (NCI)

Treatments:

Vatalanib